The FDA has given a thumbs down to Daiichi Sankyo’s HER3 antibody-drug conjugate patritumab deruxtecan. The Wednesday rejection deals … Endpoints News …
FDA rejects Daiichi’s HER3 ADC, a blow to quick approval plans for Merck partnership
Share This Story, Choose Your Platform!
About the Author:
Leave A Comment